Skip

INBUILD trial: additional analysis presented at Virtual EULAR 2020

Nuove analisi dello studio INBUILD (Nintedanib in PF-ILDs) presentate a European League Against Rheumatism (EULAR) 2020 Congress – Slide kit

banner-articoli

 

Risultati di efficacia e sicurezza per nintedanib da ulteriori analisi dello studio INBUILD:

  • Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs

  • Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases (ILDs)

  • Efficacy and safety of nintedanib in patients with autoimmune disease-related interstitial lung diseases (ILDs) treated with DMARDs and/or glucocorticoids at baseline

Visualizza contenuto

ARTICOLI CORRELATI

LEGGI
img-card
PRATICA CLINICA

Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD® trial

Risultati principali dello studio clinico di fase III INBUILD® che ha valutato efficacia e sicurezza di nintedanib in pazienti con malattie interstiziali polmonari fibrosanti progressive (PF-ILD) - Slide kit
LEGGI
LEGGI
img-card
PRATICA CLINICA

Subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial

Analisi per sottogruppi dello studio INBUILD (Nintedanib nei pazienti con PF-ILDs) – Slide kit
LEGGI
LEGGI
img-card
PRATICA CLINICA

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

Analisi dello studio INBUILD per sottogruppo di pazienti con malattie autoimmuni (Nintedanib in pazienti con PF-ILDs) – Slide kit
LEGGI